Citations

Showing 10 of 108094 citations.

Abstract 4080: New platform for novel biomarker discovery using single-cell RNA sequencing on pediatric acute myeloid leukemia samples
Schauner, Robert , Idippily, Nethrie , Karunanithi, Sheela, Manjappa, Shivaprasaad, Hwang, Tae Hyun , Wald, David N., Schauner, Robert , Jackson, Zachary , Lee, Grace

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 4080-4080

10.1158/1538-7445.am2022-4080 Get It

Abstract Pediatric Acute Myeloid Leukemia (AML) with a FLT3 internal tandem duplication (FLT3-ITD) is a challenging disease due to poor outcomes in many patients. The 4-year progression-free survival is still only 31%. Current biomarkers are insufficient to predict why certain patients with FLT3-ITD AML relapse and others do not. The development of prognostic biomarkers in FLT3-ITD pediatric AML may help improve the outcomes and management of these patients. We acquired a panel of 37 diagnostic samples with 18 samples from FLT3-ITD pediatric AML patients with poor outcomes (relapse within 3 years) and 19 from favorable outcome patients that did not exhibit relapse for at least 5 years. Next, we performed FACS to isolate CD34+CD38dim and CD34+CD38+ cells. These two populations were then sequenced using 10x Genomics 3’ end single-cell RNA sequencing (scRNAseq). Using this scRNAseq dataset comprising over 250k single cells, we first investigated if the frequency of specific RNA clusters of AML cells may predict patient outcome. We found 5 clusters had significantly different frequencies between patients with favorable and poor outcomes (p < 0.05). Using these clusters, we performed CIBERSORTx deconvolution on publicly available FLT3-ITD AML bulk RNAseq samples from TCGA (n = 36), BeatAML (n = 47), and the TARGET project (ntrain = 72; ntest = 26) to identify the inferred cluster composition present in each AML patient from these datasets. Next we built LASSO prediction models using the inferred scRNAseq clusters by CIBERSORTx and incorporating clinical features including leukemic blast percentage, bone marrow leukemic blast percentage, and WBC at diagnosis. We found these prediction models to be highly specific as a prognostic biomarker for pediatric AML (p << 0.01). We were unable to train a model directly using genes from the publicly available bulk RNAseq data for pediatric FLT3-ITD AML, highlighting the relevance of using our deconvolution based biomarker. Between the high (> median) and low (< median) LASSO score groups, there was ~50% difference in the number of patients relapsing after 4 years. When we included this LASSO score in a multivariate cox regression (likelihood ratio p value = 0.007), the LASSO score (HR = 6.8, p = 0.026, CI = 1.26 - 37.28) showed additional predictive ability when including FLT3-ITD allelic ratio (HR = 1.83, p = 0.38, CI = 0.47 - 7.15) and MRD (HR = 3.95, p = 0.021 CI = 0.051 - 0.79). These results demonstrate that incorporating rare AML cell populations into a prognostic biomarker could add substantial clinical information to existing biomarkers. This indicates single-cell derived prognostic models can and should be explored further for pediatric FLT3-ITD AML and demonstrates a platform that could be used for other malignancies, including non-hematologic tumors, to create cell-type biomarkers. Citation Format: Robert Schauner, Zachary Jackson, Nethrie Idippily, Grace Lee, Sheela Karunanithi, Shivaprasaad Manjappa, Tae Hyun Hwang, David Wald. New platform for novel biomarker discovery using single-cell RNA sequencing on pediatric acute myeloid leukemia samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4080.
Abstract 953: MEK/ERK induces the EMT transcription factor ZEB1 that is regulated by USP10 and promotes colorectal cancer metastasis that can be inhibited by BRAFV600E-directed therapy
Qin, Bo , Qin, Bo, Sun, Lei, Sinicrope, Frank A.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 953-953

10.1158/1538-7445.am2022-953 Get It

Abstract Background: Constitutive MEK-ERK activation induced by BRAFV600E or RAS mutation promotes tumor metastasis in CRC that is mediated by transcription factors regulating epithelial-to-mesenchymal transition (EMT). We determined the role of ZEB1, an EMT master transcription factor, and its potential regulation by the ubiquitin specific peptidase 10 (USP10), in tumor metastasis mediated by MEK-ERK. Materials and Methods: Isogenic RKO [BRAFV600E or wild-type (wt)] and Colo320 (BRAF/KRAS wt/wt) human CRC cells were utilized. Colo320 cells were transfected with mutant KRASG12D. In addition to parental cells, we generated USP10 shRNA expressing RKO and Colo320 cells. Cells were treated with the MEK1/2 inhibitor cobimetinib or BRAF inhibitor encorafenib. Cell migration was analyzed by wound healing and transwell assays. Protein/protein interaction was analyzed by immunoprecipitation. Protein ubiquitination level was determined by ubiquitination assay. In an orthotopic model, lung metastases in mice were generated by tail vein injection of RKO cells. Results: We demonstrate MEK-ERK activation, induced by BRAFV600E, promotes CRC metastasis through inhibition of the USP10-ZEB1 axis. USP10 is shown to interact with ZEB1 and to remove its K27 linkage ubiquitination chain, thus increasing K48 ubiquitination of ZEB1 protein that results in proteosome-mediated degradation of ZEB1. MEK-ERK induced the phosphorylation of USP10 that is shown to attenuate the USP10-ZEB1 interaction and results in ZEB1 stabilization in RKO and Colo320 cell lines. Increased ZEB1 expression promotes tumor cell migration in vitro and metastasis in a murine xenograft model that could be suppressed by cobimetinib or BRAFV600E-directed therapy with encorafenib and cetuximab. Conclusions: Targeting RAF/RAS-driven MEK/ERK signaling can suppress ZEB1 stabilization to inhibit tumor metastasis. Suppression of metastasis occurs by a novel mechanism of ZEB1 stabilization that is regulated by an atypical USP10 deubiquitinase activity. Citation Format: Bo Qin, Lei Sun, Frank A. Sinicrope. MEK/ERK induces the EMT transcription factor ZEB1 that is regulated by USP10 and promotes colorectal cancer metastasis that can be inhibited by BRAFV600E-directed therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 953.
Abstract 977: Mapping bone marrow metastasis in neuroblastoma by deep multiplex imaging and transcriptomics
Lazic, Daria , Kromp, Florian , Rifatbegovic, Fikret , Bernkopf, Marie , Ambros, Inge M. , Ladenstein, Ruth , Ostalecki, Christian , Repiščák, Peter , Mívalt, Filip , Halbritter, Florian , Bileck, Andrea , Ussowicz, Marek , Ambros, Peter F. , Gerner, Christopher , Taschner‐Mandl, Sabine

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 977-977

10.1158/1538-7445.am2022-977 Get It

Abstract Introduction: Neuroblastoma is the most common solid tumor in infants and arises from progenitor cells during sympathoadrenal development. While the majority of primary tumor cells resembles adrenergic neurons, more undifferentiated mesenchymal or neural-crest cell-like phenotypes have been found, especially in pretreated and high-risk cases. In most high-risk neuroblastoma patients, tumor cells have disseminated to the bone marrow. Problem Statement and Aim: However, the bone marrow, as a key regulator of hematopoietic and mesenchymal stem cell quiescence, is a frequent site of dissemination not only of neuroblastoma but also of other solid cancers such as breast and prostate cancer. Still, comprehensive single-cell analyses of bone marrow metastases, i.e. disseminated tumor cells (DTCs) and cells of their microenvironment, have not yet been undertaken. Herein, we aimed to capture tumor heterogeneity and investigate microenvironmental changes in a solid cancer with bone marrow involvement. Methods: To that end, we applied a multi-omics data mining approach to define a multiplex imaging panel and designed DeepFLEX, a computational pipeline for subsequent multiplex image analysis. Thereby, we obtained a single-cell map of over 35,000 DTCs and cells of their microenvironment in the metastatic bone marrow niche. In addition, we independently profiled the transcriptome of 38 patients with and without bone marrow metastasis. Results: We revealed vast diversity among DTCs and suggest that FAIM2 can act as a complementary marker to capture DTC heterogeneity. However, DTCs in this study mainly expressed markers of the adrenergic lineage, such as GD2, but did not show a mesenchymal phenotype. Interestingly, we demonstrate that malignant bone marrow infiltration is associated with an inflammatory response and at the same time the presence of immuno-suppressive cell types, most significantly an immature neutrophil/granulocyte-myeloid derived suppressor-like cell type. Conclusion: Our findings demonstrate a high level of heterogeneity among DTCs and suggest that the latter shape the bone marrow microenvironment, warranting deeper investigations of spatio-temporal dynamics at the single-cell level and their clinical relevance. Citation Format: Daria Lazic, Florian Kromp, Fikret Rifatbegovic, Peter Repiscak, Filip Mivalt, Florian Halbritter, Marie Bernkopf, Andrea Bileck, Marek Ussowicz, Inge M. Ambros, Peter F. Ambros, Christopher Gerner, Ruth Ladenstein, Christian Ostalecki, Sabine Taschner-Mandl. Mapping bone marrow metastasis in neuroblastoma by deep multiplex imaging and transcriptomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 977.
Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial
Fan, Cheng , Gibbs, Richard A. , Sanati, Souzan , Watson, Mark , Dockter, Travis , Hahn, Olwen, Guenther, Joseph M., Caudle, Abigail S. , Crouch, Erica M. , Tiersten, Amy , Mita, Monica , Razaq, Wajeeha, Leitch, A. Marilyn , Unzeitig, Gary, Winer, Eric, Weiss, Anna , Hunt, Kelly, Cynthia, X. , Ellis, Matthew J. , Anurag, Meenakshi , Hoog, Jeremy , Fernández-Martínez, Aranzazu , Vij, Kiran R , Watson, Mark, Crouch, Erica, Hieken, Tina J. , Wang, Yang , Partridge, Ann H. , Perou, Charles M. , Suman, Vera J. , Carey, Lisa A.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: CT026-CT026

10.1158/1538-7445.am2022-ct026 Get It

Abstract Introduction: The ALTERNATE trial randomized postmenopausal women with ER Allred 6-8 HER2- breast cancer to 6 months of NET with anastrozole (A), fulvestrant (F) or the combination (A+F). Biopsies were taken preNET and after 4-weeks(wks). Patients with Ki67 values >10% at 4-wks were offered triage to neoadjuvant chemotherapy. Patients with on-treatment Ki67 ≤ 10% who completed NET underwent surgery and Ki67 was reassessed. The primary endpoint was endocrine-sensitive disease rate (ESDR). ESD is defined as pCR or PEPI-0 residual disease (pT1-2, pN0, Ki67 ≤ 2.7%). We previously reported that the ESDR difference between the F-containing arms and the A arm was not >10% (ASCO 2020) and that baseline RNA-seq-based intrinsic subtypes predicted outcomes overall (SABCS 2021). Herein we describe relationships between PAM50 intrinsic subtype and Ki67 values by treatment arm because comparative drug effectiveness in adjuvant endocrine therapy studies in ER+ HER2- breast cancer can be predicted by the degree of Ki67 suppression (PMC3518447). Methods: 743 of the 1297 eligible patients (A: 264; F: 231; A+F: 248) had RNA extracted from preNET frozen tumor biopsies with >50% tumor content and subjected to RNA seq. Intrinsic subtypes were then assigned as LumA, LumB, and NonLum (Basal or HER2-E) using open-source PAM50-based informatics. Differences in the proportion with wk4 Ki67 > 10%, % change in wk4 ki67, and surgical CCCA (Ki67 ≤ 2.7%) rate (sxCCCA) between treatments and by intrinsic subtype was assessed using stratified logistic regression, Wilcoxon rank sum test, and Fisher’s exact test, respectively. Analysis of sxCCCA excluded those who failed to complete NET for reasons other than disease progression or early Ki67 >10%. Results: Amongst the 358 LumA cases there were no significant differences in Ki67-based endpoints between treatments. Among the 292 LumB cases, the wk4 ki67 > 10% rate was lower with A+F (19.4%) than A (43%) (P=0.0002) and was somewhat lower in F (31%) versus A (P=0.076). The % change in wk4 Ki67 in LumB cases, adjusted for baseline Ki67, showed markedly superior suppression for A+F versus A (-90% vs. -77%; P=<0.0001) and versus F (-90% vs. -80%; P=0.0026). Furthermore sxCCCA rates were significantly higher with A+F than A (53% vs. 25% P = <0.0001) and somewhat higher for F (37%) than A (p=0.068), indicating that superior antiproliferative effects for A+F persist after 6 months on therapy. Lack of Ki67 suppression in response to treatment was observed in the majority of 43 NonLum samples regardless of treatment. Conclusion: The combination of A+F was significantly more effective than either drug alone for the control of LumB breast cancer cell proliferation. This suggests that A+F may be a more effective adjuvant endocrine therapy than A alone in LumB disease. The lower Ki67 suppression with A alone also suggests that poorer outcome in some LumB tumors may be due to insufficient ER targeting rather than ER-independent tumor growth Support: U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868 (NRG), NCI BIQSFP, BCRF, Genentech, AstraZeneca. https://acknowledgments.alliancefound.org. (MJE) CPRIT RR140033, P50-CA186784, P50-CA58223, U01-CA214125, U24-CA210954, Gift from Ralph and Lisa Eads, McNair Scholarship. ClinicalTrials.gov Identifier: NCT01953588 Citation Format: Matthew J. Ellis, Meenakshi Anurag, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard Gibbs, Souzan Sanati, Kiran Vij, Mark Watson, Travis Dockter, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erica Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, A. Marilyn Leitch, Gary W. Unzeitig, Eric Winer, Anna Weiss, Kelly Hunt, Ann H. Partridge, Charles M. Perou, Vera Suman, Cynthia X. Ma, Lisa A. Carey. The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT026.
Modeling of Critically Ill Patient Pathways to Support Intensive Care Delivery
Trevena, William , Lal, Amos , Cubro, Edin, Zhong, Xiang , Dong, Yue , Gajić, Ognjen, Lal, Amos , Dong, Yue , Zec, Simon , Gajic, Ognjen

Mayo Clinic

IEEE Robotics and Automation Letters | June 15, 2022 | Volume: 7 | Issue: 3 | Pages: 7287-7294

10.1109/lra.2022.3183253 Get It

Abstract CT036: CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Shah, Paras , Uchio, Ed, Lamm, Donald L. , Bivalacqua, Trinity J. , McAdory, John, Burke, James , Li, Roger , Steinberg, Gary D. , Packiam, Vignesh T. , Kamat, Ashish M. , Chisamore, Michael Jon , Grandi, Paola, Kim, Jeehyun

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: CT036-CT036

10.1158/1538-7445.am2022-ct036 Get It

Abstract Introduction: CG0070, is an Ad5-based oncolytic vaccine engineered to express GM-CSF and replicate selectively in tumor cells with mutated or deficient RB. The CG0070 mechanism of action includes cell lysis and immunogenic cell death which is enhanced in the presence of GM-CSF. In an open label ph. 2 study, an overall CR rate of 62% and a CR at 12 months (m) of 29% have been observed in patients with high risk NMIBC previously treated with BCG. IV pembrolizumab, was recently approved by the FDA for patients with BCG-unresponsive CIS (with or without papillary tumors) with an overall complete RR of 41% and a 12 m CR rate of ~20%.This ph. 2 study will assess the potential synergy of the two agents in the treatment of BCG-unresponsive NMIBC. Methods:35 pts with BCG-unresponsive CIS with or without concurrent Ta or T1 disease will be treated with intravescical CG0070 (1x1012 vp) in combination with pembrolizumab at a dose of 400 mg IV q6 weeks. CG0070 will be administered weekly x 6 as induction followed by weekly x 3 maintenance instillations at months 3, 6, 9, 12, and 18. Pts with persistent CIS or HG Ta at 3 m may receive re-induction with weekly x 6 of CG0070. Pembrolizumab will be administered up to 24 m. Assessment of response will include q 3 m cystoscopy with biopsy of areas suspicious for disease, urine cytology, CTU/MRU, and mandatory bladder mapping biopsies at 12 m. Recurrence of HG disease will be enumerated as disease recurrence. The primary endpoint of the study is CR at 12 m. Secondary endpoints will include CR at any time, progression free survival, duration of response, cystectomy free survival and the safety of the combination. Correlate assessments will include changes in the tumor immune microenvironment, systemic immune induction, viral replication and transgene expression. Baseline expression of PD-L1, coxsackie adenovirus receptor, E2F transcription factor as well as anti-Ad5 Ab titer will be correlated with tumor response. Results: Thus far, 10 patients are evaluable at the 3 m timepoint for efficacy. Assessment of these 10 pts demonstrates 100% CR at 3 mos. Six of the 10 pts have also reached the 6 m hallmark in a CR as well as 2 at the 12 mos timepoint. Treatment related AE have been limited to transient grade 1-2 local-regional genitourinary adverse events with no grade 3 or 4 treatment related AE reported date. Conclusions: This initial data on the efficacy and safety of CG0070 plus pembrolizumab for the treatment of BCG unresponsive NMIBC is encouraging. An update on the study will be provided at the time of presentation. Citation Format: Roger Li, Gary Steinberg, Paras Shah, Ed Uchio, Donald Lamm, Trinity Bivalacqua, Vignesh Packiam, Ashish Kamat, Michael Chisamore, John McAdory, Paola Grandi, Jee-Hyun Kim, James Burke. CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT036.
Abstract 1784: Functional characteristics of chemotherapy-resistance in triple negative breast cancer
Emch, Michael J. , Hawse, John R. , Wang, Xiyin

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 1784-1784

10.1158/1538-7445.am2022-1784 Get It

Abstract Background: Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death among women worldwide. Triple negative breast cancer (TNBC) is an aggressive subtype representing 15-20% of all breast cancers. TNBC often ends with a poor clinical outcome due to high histological grade and recurrence rates with few treatment options. Chemotherapy remains the standard of care for TNBC treatment, but unfortunately, patients frequently develop resistance, and alternative treatment strategies for chemoresistant disease remain a major unmet need. ERβ, a second form of the estrogen receptor, is known to be expressed in approximately 20-30% of TNBC, and ligand-mediated activation of ERβ elicits potent anti-cancer effects in chemosensitive TNBC. However, the utility of ERβ in the chemoresistant setting remains unclear. Materials and methods: To study the mechanistic basis of chemoresistance in TNBC cells and identify alternative treatment approaches for chemotherapy-resistant disease, doxorubicin-resistant (Doxo-R) and paclitaxel-resistant (Taxol-R) cell lines were generated using MDA-MB-231 cells. A Doxycycline (dox) inducible expression system was used to overexpress ERβ in these cells. RNA sequencing and transcription factor (TF) activation profiling was performed to glean a comprehensive mechanistic insight into mechanisms of resistance and the functions of ERβ, and the efficacy of ERβ targeted therapies, were assessed. Results: Doxo-R and Taxol-R cells exhibited a 3- and 12-fold decrease in sensitivity to their respective chemotherapeutic agents. Doxo-R cells were more sensitive to paclitaxel while Taxol-R cells exhibited no changes in sensitivity to doxorubicin. Expression of ERβ had no impact on the IC50s for either chemotherapy drug. Taxol-R cells exhibited a significantly increased number of cells in the S phase. Proliferation assays revealed that ERβ targeting agents, including estradiol (E2) and the ERβ-specific agonist LY500307 (LY), led to substantial inhibition of cell proliferation, migration, and invasion when ERβ was expressed. We identified a large spectrum of genes expression changes that were acquired in Doxo-R and Taxol-R cells. These changes included 91 kinases genes in Doxo-R cells and 164 in Taxol-R cells. TF activation profiling indicated that eight and four TFs were activated more than 2-fold, including NRF1, WT1, and SATB1 in both Doxo-R and Taxol-R cells. Conclusions: Doxo-R and Taxol-R TNBC cell lines were successfully established and serve as a good model for studying the mechanisms of chemotherapy resistance and screening effective agents to reverse or treat chemoresistant disease. As in the sensitive setting, ERβ targeted therapies may represent an alternative treatment for TNBC patients with chemorefractory ERβ+ disease, a possibility that is currently being explored through a phase II clinical trial (NCT03941730). Citation Format: Xiyin Wang, Michael J. Emch, John R. Hawse. Functional characteristics of chemotherapy-resistance in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1784.
USP10-mediated ZEB1 deubiquitination regulates MEK-ERK-induced colorectal cancer metastasis
Sinicrope, Frank A. , Qin, Bo , yu, Jia, Sinicrope, Frank A , Sun, Lei

Mayo Clinic

No container title available | June 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1735411/v1 Get It

Abstract Zinc finger E-box binding homeobox 1 (ZEB1) is a transcription factor regulating epithelial to mesenchymal transition (EMT). To date, regulation of ZEB1 by key signaling pathways including RAS/RAF/MEK/ERK remains unclear, and few studies have focused on molecular associations or functional alterations of ZEB1 by post-translational modification. Here, we report an interaction of ZEB1 with the deubiquitinase USP10 that is regulated by MEK-ERK signaling. USP10 removes the K27 linkage ubiquitination chain on ZEB1 that enhances K48 polyubiquitination and promotes ZEB1 proteasomal degradation. However, constitutive activation of ERK can phosphorylate USP10 at Ser236 to impair its interaction with ZEB1 and, thereby, stabilize ZEB1 protein shown to promote colorectal cancer metastasis in mice. Conversely, inhibition of MEK-ERK blocks USP10 phosphorylation to enhance the USP10-ZEB1 interaction which can suppress ZEB1-mediated tumor cell migration and metastasis in vivo. Together, these data demonstrate a novel function of USP10 in the regulation of ZEB1 ubiquitination and protein stability that can inhibit ZEB1-mediated tumor metastasis.
Abstract 3445: Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients
Lam, Vicky T., Aredo, Jacqueline A., Kumar, Ashok V., Hung, Rayjean J., Neal, Joel W. , Wakelee, Heather A. , Han, Summer S. , Choi, Eunji , Wampfler, Jason A. , Wu, Julie , Christiani, David C. , Cheng, Iona C. , Amos, Christopher I. , Hung, Rayjean J., Backhus, Leah Monique , Yang, Ping

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 3445-3445

10.1158/1538-7445.am2022-3445 Get It

Abstract Introduction: Radiotherapy has long been examined in association with second malignancies, but the impact of radiotherapy for initial primary lung cancer (IPLC) on the risk of second primary lung cancer (SPLC) remains controversial. We evaluated associations between IPLC radiotherapy and the risks of SPLC and overall mortality among lung cancer survivors. Methods: We identified 689,785 patients diagnosed with IPLC in 1988-2013 from SEER. We applied cause-specific Cox (CSC) regression to evaluate association between IPLC radiotherapy and SPLC risk, adjusting for age at IPLC diagnosis, IPLC stage and histology, and prior history of cancer. To allow a latency period of exposure to IPLC radiotherapy on SPLC risk, we performed subgroup analyses restricted to patients who survived ≥5 and ≥10 years after IPLC diagnosis. Using Cox regression, we evaluated association between IPLC radiotherapy and overall mortality, adjusting for the same covariates used in the CSC analysis. Mediation analysis quantified the indirect effect of IPLC radiotherapy on overall mortality mediated through radiotherapy-driven SPLC diagnosis. Validation utilized data from 7,758 IPLC patients (496 SPLCs) at Mayo Clinic. Results: Of 689,785 IPLC patients, 18,818 (2.7%) developed SPLC in SEER. IPLC patients treated with radiotherapy had a reduced SPLC risk versus non-irradiated patients when evaluated at the time of initial diagnosis (cause-specific hazard ratio [csHR]=0.90, P<1x10-6). However, the association between IPLC radiotherapy and SPLC risk was reversed when analyses were restricted to those who survived at least 5 years (csHR=1.08, P=0.01) and 10 years (csHR=1.16, P=0.009), thus long-term survivors treated with IPLC radiotherapy having a significantly increased risk of SPLC. Mayo Clinic data showed consistent results, with the effect of IPLC radiotherapy increasing from csHR of 2.41 (P<1x10-6) to 3.38 (P=0.001) among 5-year and 10-year survivors, respectively. Similarly, compared to non-irradiated patients, those treated with IPLC radiotherapy showed a significantly increased risk of overall mortality among 10-year survivors (hazard ratio [HR]=1.46, P<1x10-6 in SEER and HR=1.54, P=5.1X10-5 in Mayo Clinic). Mediation analysis showed that a substantial proportion of the total effect of IPLC radiotherapy on overall mortality—ranging from 32% to 59%—was due to radiotherapy-driven SPLC among 10-year survivors in SEER and Mayo Clinic. Conclusions: IPLC radiotherapy is associated with increased risks of SPLC and overall mortality, with its effects more pronounced among long-term survivors. Citation Format: Eunji Choi, Vicky T. Lam, Jacqueline A. Aredo, Ashok V. Kumar, Jason Wampfler, Julie T. Wu, David C. Christiani, Iona Cheng, Christopher I. Amos, Rayjean J. Hung, Leah M. Backhus, Joel W. Neal, Heather A. Wakelee, Ping Yang, Summer S. Han. Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3445.
Abstract 1019: Address breast cancer equity through virtual community oncology navigation and engagement (vCONET)
Salinas, Manisha

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 1019-1019

10.1158/1538-7445.am2022-1019 Get It

Abstract The objective of this study is to develop and test a culturally sensitive, inclusive, and accessible virtual navigation model for Black women to promote and improve breast cancer screening behaviors. Breast cancer is among the leading causes of cancer morbidity and mortality globally, and there is a wide range of racial and ethnic disparities across the cancer continuum. Black women continue to have disproportionately high mortality rates compared to Whites, and are more impacted by triple-negative breast cancer and inflammatory breast cancer earlier in their lives and at more advanced stages. Patient navigation, particularly when culturally tailored to the intended population, is highly effective in reducing the complexity of access to care for cancer prevention and treatment. The growing momentum and usage of telehealth and virtual care has significant potential to reach Black women, to promote higher mammography screening and early detection of breast cancer. Virtual patient navigation can provide a safe, engaging, and accessible space to accelerate the application of practical approaches to address health disparities and increase preventive behaviors in underrepresented community. However, limited information exists on specific factors which impact the design, implementation, and receptivity of virtual navigation in Black communities. This study aims to: 2) Develop and test a culturally-adapted prototype of a virtual patient navigation intervention tool for increasing access to breast cancer screening education and promotion for Black women. 1) Use qualitative focus group methodology to explore the beliefs, attitudes, perceptions, and receptivity of community members of program usability and breast cancer awareness, prevention and screening behaviors among Black women. The study will examine social determinants of health that impact potential challenges to access utilization of mammography screening services. Qualitative focus group discussions will be conducted to guide the details of the virtual patient navigation, such as communication channels, specific messaging approaches, and sociocultural factors to integrate, as well as addressing current challenges and needs faced by the community. The results of this study can provide valuable insight to specific needs regarding outreach and access to screening mammography services to underrepresented communities of color to ultimately reduce breast cancer rates. Data collection is ongoing and preliminary results will be presented. Citation Format: Manisha Salinas. Address breast cancer equity through virtual community oncology navigation and engagement (vCONET) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1019.